|Day's Range||85.51 - 86.57|
|52 Week Range||66.93 - 86.90|
|PE Ratio (TTM)||32.46|
|Dividend & Yield||2.72 (3.15%)|
|1y Target Est||N/A|
Is fast-rising Exelixis a better stock pick than huge drugmaker Novartis?
All major pharma stocks were up this week with companies like Novartis (NVS) presenting positive data and others gaining FDA approval.
A European Medicines Agency (EMA) panel recommended on Friday approving Novartis's Kisqali drug, bolstering the Swiss drugmaker's bid to challenge rival Pfizer's Ibrance against tough-to-treat breast cancer. The EMA's Committee for Medicinal Products for Human Use (CHMP) backed Kisqali in combination with hormone therapy as a first-line treatment for hormone receptor positive, human epidermal growth factor receptor-2 negative locally advanced or metastatic breast cancer. This latest CHMP opinion sets the stage for likely European Commission approval this year.